Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. - Wikidata - wikimedia - TriplyDB

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

http://www.wikidata.org/entity/Q34916352

about

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis Hypertension in patients with cancer Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma Individualising treatment choices in a crowded treatment algorithm Circulating biomarkers in advanced renal cell carcinoma: clinical applications Investigation of Tumor Cell Behaviors on a Vascular Microenvironment-Mimicking Microfluidic Chip.Drug-induced glomerular disease: direct cellular injury.The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives Sunitinib in the treatment of metastatic renal cell carcinoma Medical treatment of renal cancer: new horizons Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension More sound cancer therapy biomarker development with active noise control.Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma.Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study.Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial Cardiovascular disease in adult survivors of childhood cancer.Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours.Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy.

P2860

Q26751341-6C28663A-3C8B-4879-8558-0F9B70D6861D Q26774515-C3C74410-F65D-493C-B8AC-41E2E416A4A8 Q26801279-E3E4E244-7212-4F54-998C-9CE93296306E Q26823035-BCE1181D-5B4D-4D4D-BCEA-442106990736 Q26996793-ABC0EFC6-F273-4ED8-86EB-744756335F41 Q27003304-4A6AA9DC-35F6-4F92-A789-E95D489D9712 Q27003980-FFF2AA51-F1BB-4E8F-BF57-E246E8E200B2 Q27013665-55326572-9A8A-436B-9EA6-1213DE8AF623 Q27023669-48B3ED21-5BBE-40CD-94D3-CFD0A80F0E44 Q27023770-74F016BB-1B77-464B-95E1-A342E4A9DD27 Q27304419-48DBF8CB-3156-467C-A4D4-D3E1F519088C Q27692666-7EF614F3-C364-4217-8C5D-2669966FAC37 Q27851744-0A151A09-1308-4349-8D2A-CD2FAC3C4182 Q28067482-A6D21F00-8924-4736-BCC2-E250BB8998A7 Q28069560-B86FEACA-B542-48CF-AD76-D9D53BC054DE Q28072057-BA6107B9-5F09-4FB1-8D8E-AD8D525C362C Q28073174-7C8DBC6E-B4A0-4ECB-911E-7227ABE9864F Q28080163-45E95B3C-104E-499F-B9CD-6683E8A079F6 Q28537681-73D20CE2-CB99-4597-AFA2-6543E7038CB1 Q28728389-BF4A9F03-A11A-4C19-974D-F12180CA1A4E Q30442454-C28F0674-4A04-4585-919F-1BC18C8F7A50 Q30587082-48011D09-A32C-4B26-90ED-11B95421E086 Q30671049-3893BCF4-7B30-4542-869F-8CC23BA003EE Q33417828-811ED445-C8F5-4C3A-B1D9-9E8B1D08445F Q33422376-36C86B71-163B-4A17-B2E9-4D44581196FC Q33426559-F6E208D9-736E-4D1D-AF8D-0857BAA08FE3 Q33426958-307F2B12-DA4B-44A9-98DC-A79A7C2B7478 Q33432282-B3BAE622-7926-4203-B736-EBEDC407E195 Q33441090-FDD14EC8-88BB-4F92-B54D-2FC5B80EDE7F Q33588722-E7181062-0AF2-4869-AAF0-4520825189C5 Q33633424-9722401D-9334-48E3-8F14-3C3DA050E197 Q33633431-BF2F5A75-AE24-401B-A8A1-4D3128EC03CC Q33665833-AE85FEC3-845A-420F-8B2D-A402341573A7 Q33698419-1AE83529-D57B-4094-81B8-2A65F4624537 Q33770680-9C18CE39-3524-4B96-A04D-76B0F9272580 Q33918464-7B51CD5E-A914-4D30-A66A-0A9DA7659F61 Q33997879-2EF873BB-EA01-43A5-84AF-EDBE7AFE0A24 Q34042984-98642506-3064-46D6-810D-577AA5D5B034 Q34141825-0C9EF700-1878-4D74-B0E5-5EDD15AC3E53 Q34265694-3EB06E38-13EB-41DC-B348-3FD1C90BADA7

P2860

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

http://www.wikidata.org/entity/Q34916352

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Hypertension as a biomarker of ...... cinoma treated with sunitinib.

@ast

Hypertension as a biomarker of ...... cinoma treated with sunitinib.

@en

Hypertension as a biomarker of ...... cinoma treated with sunitinib.

@nl

type

label

Hypertension as a biomarker of ...... cinoma treated with sunitinib.

@ast

Hypertension as a biomarker of ...... cinoma treated with sunitinib.

@en

Hypertension as a biomarker of ...... cinoma treated with sunitinib.

@nl

prefLabel

Hypertension as a biomarker of ...... cinoma treated with sunitinib.

@ast

Hypertension as a biomarker of ...... cinoma treated with sunitinib.

@en

Hypertension as a biomarker of ...... cinoma treated with sunitinib.

@nl

P1433

Q34916352-B66143F8-5ACA-486A-B2EF-4048C84DA1F2

P1476

Q34916352-5F7B26EB-28BC-4B98-9E30-2ACCFB2DA0ED

P2093

Q34916352-038221BF-C77D-4ABE-BCE8-7AA34C7C8DAD

Q34916352-294E948E-4C9E-4FA3-B21C-5B532389B73F

Q34916352-2F03AFEB-F3D2-4CA2-B72E-C80980B50120

Q34916352-386FFD7B-E042-4030-BE12-EE44287D57EF

Q34916352-756AC548-9781-4463-B62E-71EA9AC87B5D

Q34916352-8D12609B-9D9F-43AA-98F3-B520042CCB3C

Q34916352-AE0A554F-4B12-4687-A720-B53C7B467845

Q34916352-C313710F-891C-4C8C-8989-1BBE8E510C14

P2860

Q34916352-126D1AAE-D67F-4834-8E02-B7EECD9E81AE

Q34916352-328FAEA3-B0D6-4F31-8E1B-FE4EBC986541

Q34916352-3F1708DE-A227-4DDF-B57F-AC8E082DC6F5

Q34916352-47A4137A-AA88-4C78-B8DE-894D40260507

Q34916352-4D132343-34D8-4330-B632-58B0377A4493

Q34916352-4DE43270-3B27-4F40-ADC2-1B60CAF5959D

Q34916352-6A70B0F2-B7C2-4FF1-A70F-05AC4C4CC29C

Q34916352-6E190FE0-6D76-4FEF-85A7-71A61C402AF0

Q34916352-71389215-8F2C-457E-BB5E-6CBCA40251B7

Q34916352-81B6B843-2D76-4312-9DA2-5F66595330D9

P304

Q34916352-1049375F-9BC7-4BEC-B2DB-E8B5BA11C377

P31

Q34916352-81B0916C-D29E-4266-BC4C-43D9140CB02F

P356

Q34916352-974D9109-07FF-40EF-9CDA-EF8403729301

P407

Q34916352-1E724B97-328E-4B42-AD03-645BDA64F5F0

P433

Q34916352-36D08DB2-96E9-4799-BBF3-C88749057979

P478

Q34916352-1B2CE395-861F-4333-9FD0-9113C056B0CF

P50

Q34916352-641D8DA6-6C53-4ACB-AA26-AF5D8688A74D

P577

Q34916352-9A125925-5EA5-4A85-ABBA-EB617F0E9C82

P5875

Q34916352-06B6D218-108D-4835-8EB7-A91A02591F4A

P698

Q34916352-D56FC876-EF80-436A-B345-08BFCFD30AA9

P921

Q34916352-8FD3E914-23F5-429B-A90C-68EAFFB7AE4A

Q34916352-978B007A-40B3-4632-B5AC-DC2FD8E08530

P932

Q34916352-7CCF02E5-D043-402C-B800-7B5C2C79B22C

P356

P1433

Journal of the National Cancer Institute

P1476

Hypertension as a biomarker of ...... cinoma treated with sunitinib.

@en

P2093

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Darrel P Cohen

http://www.w3.org/2001/XMLSchema#string

Dongrui R Lu

http://www.w3.org/2001/XMLSchema#string

Isan Chen

http://www.w3.org/2001/XMLSchema#string

Martin E Gore

http://www.w3.org/2001/XMLSchema#string

Michael S Baum

http://www.w3.org/2001/XMLSchema#string

Robert A Figlin

http://www.w3.org/2001/XMLSchema#string

Subramanian Hariharan

http://www.w3.org/2001/XMLSchema#string

P2860

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib.

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

P304

763-773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJR128

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51084307

http://www.w3.org/2001/XMLSchema#string

P698

21527770

http://www.w3.org/2001/XMLSchema#string

P921

P932

3086879

http://www.w3.org/2001/XMLSchema#string